Immunome Inc (NASDAQ:IMNM) shares, rose in value on Wednesday, July 09, with the stock price up by 3.98% to the previous day’s close as strong demand from buyers drove the stock to $8.89.
Actively observing the price movement in the last trading, the stock closed the session at $8.55, falling within a range of $8.65 and $9.27. The value of beta (5-year monthly) was 1.947. Referring to stock’s 52-week performance, its high was $16.81, and the low was $5.15. On the whole, IMNM has fluctuated by -2.63% over the past month.
With the market capitalization of Immunome Inc currently standing at about $773.54 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IMNM’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of IMNM currently trading nearly -0.88% and 2.69% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.37, while the 7-day volatility ratio is showing 5.66% which for the 30-day chart, stands at 5.82%. Furthermore, Immunome Inc (IMNM)’s beta value is 1.94.
A comparison of Immunome Inc (IMNM) with its peers suggests the former has fared considerably weaker in the market. IMNM showed an intraday change of 3.98% in last session, and over the past year, it shrunk by -16.29%%.
Data on historical trading for Immunome Inc (NASDAQ:IMNM) indicates that the trading volumes over the past 10 days have averaged 1.39 and over the past 3 months, they’ve averaged 1.05 million. According to company’s latest data on outstanding shares, there are 86.96 million shares outstanding.
Nearly 11.74% of Immunome Inc’s shares belong to company insiders and institutional investors own 82.25% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.52 million shares as on 2025-06-13, resulting in a short ratio of 13.74. According to the data, the short interest in Immunome Inc (IMNM) stood at 1503.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 12.72 million. The stock has fallen by -26.10% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IMNM stock heading into the next quarter.
